Only in Titles

Search results for: Monoclonal Anti Bone Morphogenetic Protein 6 produced in mouse

paperclip

#30677788   2019/03/04 To Up

Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.

Erythropoiesis-stimulating agents used to treat anaemia in patients with chronic kidney disease (CKD) have been associated with cardiovascular adverse events. Hepcidin production, controlled by bone morphogenic protein 6 (BMP6), regulates iron homeostasis via interactions with the iron transporter, ferroportin. High hepcidin levels are thought to contribute to increased iron sequestration and subsequent anaemia in CKD patients. To investigate alternative therapies to erythropoiesis-stimulating agents for CKD patients, monoclonal antibodies, LY3113593 and LY2928057, targeting BMP6 and ferroportin respectively, were tested in CKD patients.
Matthew Sheetz, Philip Barrington, Sophie Callies, Paul H Berg, Juliet McColm, Thomas Marbury, Brian Decker, Gregory L Dyas, Stephanie M E Truhlar, Robert Benschop, Donmienne Leung, Jolene Berg, Derrick R Witcher

1675 related Products with: Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.

50 UG2 Pieces/Box2 Pieces/Box2 Pieces/BoxInhibitors96 tests

Related Pathways